TABLE 7.
Inhibition of liver-stage parasite development of sera or purified antibodies from A/J mice immunized with linear synthetic peptides in TiterMax
| Treatment | No. of schizonts in triplicate cultures | Mean ± SD | % Inhibitionb | P valuec |
|---|---|---|---|---|
| Antiseraa (1:20 final dilution) induced by: | ||||
| (SFPMNEESPLGFSPE)3 | 27, 26, 24 | 25.6 ± 1.2 | 50.8 | 0.007 |
| (GFSPEEMEAVASKFR)3 | 31, 32, 45 | 36.0 ± 6.4 | 30.8 | 0.077 |
| TiterMax control | 42, 56, 58 | 52.0 ± 7.1 | ||
| Purified antibodies (100 μg/ml) induced by: | ||||
| (SFPMNEESPLGFSPE)3 | 28, 31, 40 | 33.0 ± 5.0 | 56.0 | 0.001 |
| (GFSPEEMEAVASKFR)3 | 44, 38, 37 | 39.0 ± 2.6 | 48.0 | 0.001 |
| TiterMax control | 82, 69, 78 | 76.0 ± 5.0 |
a
Serum samples collected 10 days after second immunization of A/J mice (protected strain) with these peptides had IFA titers of 6,400. The TiterMax control sera were IFAT negative.
b
Based on the number of schizont counts in relevant TiterMax control serum or purified antibody.
c
Independent sample t test). P ≤ 0.05 was considered not significant.